Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

21. Ezetimibe plus a Statin after Acute Coronary Syndromes.

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444741 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1476. doi: 10.1056/NEJMc1509363#SA7. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444741 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

NEJM2015 Full Text: Link to full Text with Trip Pro

22. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia

Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia 25841542 2015 05 26 2015 08 03 2015 11 19 1097-6833 166 6 2015 Jun The Journal of pediatrics J. Pediatr. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. 1377-84.e1-3 10.1016/j.jpeds.2015.02.043 S0022-3476(15)00163-8 To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young (...) to daily ezetimibe 10 mg (n = 93) or placebo (n = 45) for 12 weeks. Lipid-altering efficacy and safety were assessed in all treated patients. Overall, mean age was 8.3 years, 57% were girls, 80% were white, mean baseline LDL-C was 228 mg/dL (5.9 mmol/L), and 91% had HeFH. After 12 weeks, ezetimibe significantly reduced LDL-C by 27% after adjustment for placebo (P < .001) and produced significant reductions in total cholesterol (21%), nonhigh-density lipoprotein cholesterol (26%), and apolipoprotein B

EvidenceUpdates2015

23. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 26039521 2015 06 18 2015 06 24 2016 12 14 1533-4406 372 25 2015 Jun 18 The New England journal of medicine N. Engl. J. Med. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 2387-97 10.1056/NEJMoa1410489 Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption (...) (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter

NEJM2015

24. Randomised controlled trial: Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome

Randomised controlled trial: Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome Article Text Therapeutics/Prevention Randomised controlled

Evidence-Based Medicine (Requires free registration)2015

25. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. 24825642 2014 05 14 2014 05 26 2016 10 17 1538-3598 311 18 2014 May 14 JAMA JAMA Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. 1870-82 10.1001/jama.2014.4030 In phase 2 studies (...) , evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries. Patients (n = 2067) were randomized to 1

JAMA2014 Full Text: Link to full Text with Trip Pro

26. IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin? RxFiles: Trial Summary www.RxFiles.ca - Dec 2014, Updated June 2015 Loren Regier BSP BA, Brent Jensen BSP IMPROVE-IT To add, or not to add ezetimibe EZETROL to moderate dose statin? What we already knew? ? Statins… have consistently demonstrated efficacy in lowering not only LDL, but risk of cardiovascular (CV) events +/- mortality in those with high CV risk. 1 ? Ezetimibe… 2 o has no evidence as monotherapy (...) -controlled trial design, the benefit could have been due to the statin alone. SHARP What IMPROVE-IT may add? ? Ezetimibe may modestly lower CV event risk when added to a moderate dose statin (simvastatin 40mg). IMPROVE-IT 3,4 n=18,144; stable-recent ACS, normal LDL median2.46 ? 1.4 vs 1.8mmol/L Ezetimibe 10mg +Simvastatin 40mg Simvastatin 40mg NNT P Comment Combination VYTORIN USA only used. Composite of CV death, MI, unstable angina requiring hospitalization, revascularization or stroke (1 ? Endpoint

RxFiles2014

27. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease

Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Azetidines; Coronary Diseases; Drug Combinations; Simvastatin Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

Health Technology Assessment (HTA) Database.2013

28. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease

Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation NIHR HSC. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticholesteremic Agents; Azetidiness; Cardiovascular Diseases; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors Language Published English

Health Technology Assessment (HTA) Database.2013

29. Liptruzet (ezetimibe and atorvastatin)

Liptruzet (ezetimibe and atorvastatin) Drug Approval Package: Liptruzet (ezetimibe and atorvastatin) NDA #200153 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Liptruzet (ezetimibe and atorvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg Company: Merck Sharp & Dohme Corp. Application No.: 200153 Approval Date: 05/03/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2013

30. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia van Nooten F, Davies GM, Jukema JW, Liem AH, Yap E, Hu XH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to assess the cost-effectiveness of ezetimibe in combination with simvastatin, for the treatment of patients with primary hypercholesterolaemia. The authors concluded that ezetimibe plus simvastatin appeared to be cost-effective for these patients who had not achieved

NHS Economic Evaluation Database.2012

31. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle 22633824 2012 07 09 2012 07 23 2016 11 25 1474-547X 380 9836 2012 Jul 07 Lancet (London, England) Lancet Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous (...) familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. 29-36 10.1016/S0140-6736(12)60771-5 Inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) resulted in large reductions of low-density lipoprotein cholesterol (LDL-C) in phase 1 trials. We assessed the efficacy and safety of various doses and dosing intervals of REGN727, a monoclonal antibody to PCSK9, added to statins, to further lower LDL-C in

Lancet2012

32. Ezetimibe for hypercholesterolaemia

Ezetimibe for hypercholesterolaemia Executive Summary IQWiG Reports - Commission No. A10-02 Ezetimibe for hypercholesterolaemia 1 1 Translation of the executive summary of the final report “Ezetimib bei Hypercholesterinämie” (Version 1.0; Status: 18.07.2011). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive summary of final report A10-02 Version 1.0 (...) Ezetimibe for hypercholesterolaemia 18.07.2011 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ezetimibe for hypercholesterolaemia Contracting agency: Federal Joint Committee Commission awarded on: 20.05.2010 Internal Commission No.: A10-02 Address of publisher: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel: +49-(0)221/35685-0 Fax: +49-(0)221

Institute for Quality and Efficiency in Healthcare (IQWiG)2012

33. Colesevelam (Cholestagel) - in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia

Colesevelam (Cholestagel) - in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia Published 07 February 2011 Statement of Advice: colesevelam 625mg film-coated tablets (Cholestagel®) (SMC No: 690/11) Genzyme Therapeutics 14 January 2011 ADVICE: in the absence of a submission from the holder of the marketing authorisation colesevelam (Cholestagel®) is not recommended for use within NHS (...) Scotland. Indication under review: in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents

Scottish Medicines Consortium2011

34. [Ezetimibe for hypercholesterolaemia]

[Ezetimibe for hypercholesterolaemia] Ezetimib bei Hypercholesterinämie [Ezetimibe for hypercholesterolaemia] Ezetimib bei Hypercholesterinämie [Ezetimibe for hypercholesterolaemia] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Ezetimib bei Hypercholesterinämie. [Ezetimibe for hypercholesterolaemia] Cologne: Institut fuer (...) Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 90. 2011 Authors' objectives In its letter of 20 May 2010, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess ezetimibe (in mono- or combination therapy) in patients with hypercholesterolaemia. Authors' conclusions In patients with hypercholesterolaemia there is no proof of a benefit or harm from ezetimibe therapy compared with placebo. This applies both

Health Technology Assessment (HTA) Database.2011

35. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Mikhailidis DP, Lawson RW (...) , McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K CRD summary This review concluded that the addition of ezetimibe to a statin was more effective in reducing low-density lipoprotein cholesterol and enabling more patients to achieve their goal, than doubling the dose of statin monotherapy, for the treatment of primary hypercholesterolaemia. These conclusions should be interpreted with caution due to the substantial variation observed for the pooled outcomes. Authors' objectives To assess

DARE.2011

36. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 21663949 2011 06 27 2011 07 18 2016 12 28 1474-547X 377 9784 2011 Jun 25 Lancet (London, England) Lancet The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 2181-92 (...) 10.1016/S0140-6736(11)60739-3 Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients. This randomised double-blind trial included 9270 patients with chronic kidney disease

Lancet2011 Full Text: Link to full Text with Trip Pro

37. SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease

SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease SHARP: Study of Heart & Renal Protection 1-2 The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease TRIAL BACKGROUND • Prevalence of CKD is steadily climbing in Canada. CVD is the leading cause of death in CKD ~10-30 fold higher than general population . • In late-stage CKD GFR 150umol (...) ) Jill Hall, BScPharm & Aleesa Carter, BSP, PharmD Candidates COMMENTS • Revised 1 ° outcome is likely the better outcome since it allows determination of benefit from statins by looking at outcomes statins are known to impact; controversy settled when results between the 2 outcomes were similar and power was adequate for both • Cannot conclude if benefit secondary to addition of ezetimibe to statin therapy vs. statin therapy alone; however, lack of clinical benefit despite expected LDL reduction in

RxFiles2011

38. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study)

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study) 21029821 2010 10 29 2010 12 02 2015 11 19 1879-1913 106 9 2010 Nov 01 The American journal of cardiology Am. J. Cardiol. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with (...) and safety of the usual starting dose of ezetimibe/simvastatin (10/20 mg) versus atorvastatin 10 or 20 mg and the next higher dose of ezetimibe/simvastatin (10/40 mg) versus atorvastatin 40 mg in 1,289 hypercholesterolemic patients ≥65 years of age with or without cardiovascular disease. Patients randomized to ezetimibe/simvastatin had greater percent decreases in LDL cholesterol (-54.2% for 10/20 mg vs -39.5% and -46.6% for atorvastatin 10 and 20 mg, respectively; -59.1% for 10/40 mg vs -50.8

EvidenceUpdates2010

39. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets 20487050 2010 07 20 2011 11 10 2015 11 19 1742-1241 64 8 2010 Jul International journal of clinical practice Int. J. Clin. Pract. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised (...) controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. 1052-61 10.1111/j.1742-1241.2010.02429.x The aim of this study was to compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the Joint British Societies (JBS)-2 and National Institute for Health and Clinical Excellence low-density-lipoprotein cholesterol (LDL-C) target of < 2 mmol/l for secondary prevention or JBS-2 LDL-C target of < 2 mmol

EvidenceUpdates2010

40. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study)

Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study) 20185012 2010 02 26 2010 04 06 2015 11 19 1879-1913 105 5 2010 Mar 01 The American journal of cardiology Am. J. Cardiol. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). 656-63 (...) 10.1016/j.amjcard.2009.10.029 Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients > or = 65 years of age. The percentage of change from baseline in low-density lipoprotein (LDL) cholesterol and the percentage of patients achieving prespecified LDL cholesterol levels after 12 weeks of ezetimibe 10 mg plus atorvastatin versus up titration of atorvastatin were assessed in subjects > or = 65 years old with hyperlipidemia and at high risk of coronary

EvidenceUpdates2010